JP2012126736A5 - - Google Patents

Download PDF

Info

Publication number
JP2012126736A5
JP2012126736A5 JP2012062968A JP2012062968A JP2012126736A5 JP 2012126736 A5 JP2012126736 A5 JP 2012126736A5 JP 2012062968 A JP2012062968 A JP 2012062968A JP 2012062968 A JP2012062968 A JP 2012062968A JP 2012126736 A5 JP2012126736 A5 JP 2012126736A5
Authority
JP
Japan
Prior art keywords
mycobacterial
product
extract
acid compound
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012062968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012126736A (ja
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed filed Critical
Publication of JP2012126736A publication Critical patent/JP2012126736A/ja
Publication of JP2012126736A5 publication Critical patent/JP2012126736A5/ja
Pending legal-status Critical Current

Links

JP2012062968A 1997-04-01 2012-03-21 炎症性腸疾患を治療するための方法および組成物 Pending JP2012126736A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO5940 1997-04-01
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease
AUPO9785 1997-10-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007232402A Division JP2008024713A (ja) 1997-04-01 2007-09-07 炎症性腸疾患を治療するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2012126736A JP2012126736A (ja) 2012-07-05
JP2012126736A5 true JP2012126736A5 (enExample) 2013-05-09

Family

ID=25645389

Family Applications (3)

Application Number Title Priority Date Filing Date
JP54099898A Withdrawn JP2001524951A (ja) 1997-04-01 1998-04-01 炎症性腸疾患を治療するための方法および組成物
JP2007232402A Withdrawn JP2008024713A (ja) 1997-04-01 2007-09-07 炎症性腸疾患を治療するための方法および組成物
JP2012062968A Pending JP2012126736A (ja) 1997-04-01 2012-03-21 炎症性腸疾患を治療するための方法および組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP54099898A Withdrawn JP2001524951A (ja) 1997-04-01 1998-04-01 炎症性腸疾患を治療するための方法および組成物
JP2007232402A Withdrawn JP2008024713A (ja) 1997-04-01 2007-09-07 炎症性腸疾患を治療するための方法および組成物

Country Status (16)

Country Link
US (1) US6277836B1 (enExample)
EP (1) EP0971735B1 (enExample)
JP (3) JP2001524951A (enExample)
AR (1) AR012304A1 (enExample)
AT (1) ATE389417T1 (enExample)
CA (1) CA2285923C (enExample)
CY (1) CY1109783T1 (enExample)
DE (1) DE69839261T2 (enExample)
DK (1) DK0971735T3 (enExample)
ES (1) ES2303351T3 (enExample)
IL (1) IL132145A (enExample)
NO (1) NO325947B1 (enExample)
NZ (1) NZ500696A (enExample)
PT (1) PT971735E (enExample)
SI (1) SI0971735T1 (enExample)
WO (1) WO1998043667A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
DE60043216D1 (de) * 1999-02-12 2009-12-10 Univ Washington Gm-csf zur behandlung von morbus crohn
CZ302015B6 (cs) * 1999-10-08 2010-09-08 Affinium Pharmaceuticals, Inc. Inhibitory Fab I
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
HRP20020781A2 (en) * 2000-03-28 2004-12-31 Biochemie Gmbh Granulated particles with masked taste
WO2002018324A2 (en) * 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド FabI阻害剤
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
PT1575951E (pt) * 2002-12-06 2014-09-15 Debiopharm Int Sa Compostos heterocíclicos, métodos para os preparar e sua utilização em terapia
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
US7417037B2 (en) 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
NZ549661A (en) 2004-02-06 2010-07-30 Pharmatel R & D Pty Ltd As Tru Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ, インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
WO2007053131A2 (en) 2004-06-04 2007-05-10 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as antibiotic agents
EP1773767B1 (en) 2004-07-07 2016-03-09 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
CN101247812A (zh) * 2005-08-24 2008-08-20 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP2009518399A (ja) * 2005-12-05 2009-05-07 アフィニウム ファーマシューティカルズ, インク. Fabi阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
WO2009064953A1 (en) * 2007-11-15 2009-05-22 Enanta Pharmaceuticals, Inc. Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
HRP20190045T1 (hr) * 2008-02-08 2019-03-08 Red Hill Biopharma Ltd. Metode i sastavi za liječenje upalne bolesti crijeva
RU2010143460A (ru) * 2008-05-01 2012-06-10 Дзе Проктер Энд Гэмбл Компани (US) Способы и наборы для терапии восстановительных состояний кишечника
WO2011044140A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
AU2010312309B2 (en) 2009-10-26 2016-10-06 Thomas Julius Borody Novel enteric combination therapy
US8497256B2 (en) 2010-04-26 2013-07-30 Salix Pharmaceuticals, Ltd Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
NZ611868A (en) 2010-12-13 2015-11-27 Salix Pharmaceuticals Inc Gastric and colonic formulations and methods for making and using them
TWI573590B (zh) 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
HRP20190980T1 (hr) 2012-06-19 2019-08-23 Debiopharm International Sa Derivati predlijeka (e)-n-metil-n((3-metilbenzofuran-2 il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamida
EP2877163B1 (en) 2012-07-27 2019-03-20 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
CA2953110C (en) * 2014-05-22 2018-10-30 John Todd Kuenstner Treatment of diseases caused by mycobacterium avium using a combination of ultraviolet blood irradiation and antibiotics
AU2017223037B2 (en) 2016-02-26 2022-04-14 Debiopharm International S.A. Medicament for treatment of diabetic foot infections
US12403131B2 (en) 2019-02-14 2025-09-02 Debiopharm International S.A. Afabicin formulation, method for making the same and uses thereof
MX2021015513A (es) 2019-06-14 2022-04-20 Debiopharm Int Sa Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelicula.
EP4171546A4 (en) 2020-06-30 2024-03-13 Redhill Biopharma Ltd. TRIPLE ANTIBIOTIC SOLID DOSE COMBINATION PRODUCTS, DOSAGE SCHEME, METHOD AND KITS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS NON-TUBERCULOSIS
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Similar Documents

Publication Publication Date Title
JP2012126736A5 (enExample)
IL277110B2 (en) Immunogenic anti-inflammatory preparations
JP2015522630A5 (enExample)
JP2014528474A5 (enExample)
JP2018507914A5 (enExample)
JP5781606B2 (ja) インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用
JP2016530239A5 (enExample)
JP2012126736A (ja) 炎症性腸疾患を治療するための方法および組成物
JP2015057451A5 (enExample)
JP2016074740A5 (enExample)
JP2015529225A5 (enExample)
JP2018513188A5 (enExample)
JP2014532704A5 (enExample)
JP2014526503A5 (enExample)
JP2013541583A5 (enExample)
JP2012517427A5 (enExample)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2021509395A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2017533220A5 (enExample)
JP2014507475A5 (enExample)
JP2016505050A5 (enExample)
JP2017514858A5 (enExample)
JP2016512247A5 (enExample)
JP2014148552A5 (enExample)